 Volver a la Página Principal |
PUBLICACIONES
FEHV
1.
Carreño V, Navarro A, Hernández-Guío C. Epidemiología de la
hepatitis B. Rev Esp Enf Ap Dig 1979; 56: 589-596.
2.
Carreño V, Navarro A, Hernández-Guío C. Hepatitis viral aguda en
nuestro medio. Rev
Soc And Pat Digest 1979; Tomo II: 207-214.
3.
Carreño V, Navarro A, Hernández-Guío C. Virus de la
hepatitis. Rev
Esp Enf Ap Dig 1979; 56: 475-484.
4.
Carreño V, Navarro A, Ortiz F, Hernández-Guío C. Virus de la
hepatitis B y personal hospitalario. Rev
Clin Esp 1980; 157: 179-182.
5.
Aquino MA, Carreño V,
Porres JC, Hernández-Guío C. Alteraciones hepáticas en los
drogadictos.
Gastroenterol Hepatol 1980; 4: 356-359.
6. García
Mas JL, Carreño V, Hernández-Guío
C. Valor de la GGTP en el estudio de las enfermedades
hepatobiliares; su
comparación con los parámetros bioquímicos habituales. Rev
Esp Enf Ap Dig 1981; 59: 597-602.
7.
Carreño V. Pronóstico, evolución y tratamiento de la
hemocromatosis. Gastrum 1981; 6: 80-90.
8.
Carreño V. Pronóstico, evolución y tratamiento de la
CBP. Gastrum
1981; 6: 42-51.
9.
Carreño V, Porres JC, Hernández‑Guío C, Marina Fiol C,
Alvarez C, Hernando L. The significance of hepatitis B infection to
nurses, paramedics and laboratory workers. Proc Eur Symp Hepatitis
B. 1981; 27‑38. Ed. S. Krugman and S.Sherlock, MSD Int.,
Rahway.
10.
Weller IVD, Carreño V,
Fowler MJF, Monjardino J, Maniken D, Thomas HC, Sherlock S. Acyclovir
inhibits hepatitis B virus replication in man. Lancet 1982; i: 273.
11.
Weller IVD, Fowler MJF, Monjardino J, Carreño
V, Thomas HC, Sherlock S. Inhibition of hepatitis B viral replication
by lymphoblasted interferon. Phil Trans R Soc Lond (Biol) 1982; 299 (1094):
128-130.
12.
Carreño V. Hepatitis viral aguda. Ed. Europharma.
1982; 5-15.
13.
Carreño V. Virus No‑A,No‑B de la hepatitis: progresos
realizados. Rev
Clin Esp 1982; 167: 139-141.
14.
Weller IVD, Carreño V,
Fowler MJF, Monjardino J, Makinen D, Varghese Z, Sweny P, Thomas HC, Sherlock
S. Acyclovir in hepatitis B antigen‑positive chronic liver
diseases:
inhibition of viral replication and transient renal impairment with iv bolus
administration. J Antimicrobial Chemother 1983; 11: 223-231.
15.
Montaño L, Carreño V,
Ortiz O. Replicación viral y cambios en la expresión de los antígenos
tisulares HBs y HBc en pacientes con hepatitis viral crónica tipo B. Rev Clin
Esp 1983; 169: 99-101.
16.
Carreño V, González R, Porres JC, Ortíz F, Martín F, Hernández‑Guio
C. Prevalencia de anti‑HAV en la población
española. Rev
Esp Enf Ap Dig 1983; 64: 187-190.
17.
Escuin F, Conesa J, Sanz A, Selgas R, Pérez M, Torres A, Ara JM, Gómez
P, Carreño V, Lardinois R, Sánchez-Sicilia
L. Vacunación contra hepatitis B en una unidad de
diálisis. Nefrología
1983; 3: 287-293.
18.
Carreño V, Montaño L, De Torres M. Tratamiento de la
hepatitis
crónica por virus B. Rev Clin Esp 1983; 171: 73-76.
19.
Mora I, Porres JC, Carreño V. Marcadores
serológicos del virus B de la hepatitis (VBH). Progresos realizados. Rev
Clin Esp 1984; 173: 9-14.
20.
Carreño V. Tratamiento de las hepatitis crónicas por virus
B. Gastroenterol. Hepatol 1984 (Editorial); 7: 45-47.
21.
Carreño V, Porres JC, Mora I, Hernández‑Guío C. Utilidad
de la determinación de actividad DNA polimerasa del virus B de la hepatitis
(VBH‑DNAp)
en portadores crónicos de AgHBs. Rev
Clin Esp 1984; 174: 75-77.
22.
Porres JC, Carreño V, Hernández‑Guío
C. Estudio prospectivo de hepatitis agudas por virus A, B y No‑A,
No‑B: diferencias epidemiológicas y clínicas. Rev
Clin Esp 1984; 174: 31-34.
23.
Bas C, Carreño V, Porres
JC, Mora I, Gutiez J, De Torres M, Hernández‑Guío C. Sobreinfección
con agente delta en portadores crónicos de AgHBs en España. Características
clínicas, epidemiológicas y virológicas. Rev
Clin Esp 1984; 175: 67-69.
24.
Carreño V, Porres JC, Gutiez J, Hernández‑Guío C.
Reactivación vírica en hepatitis crónica por virus B con bajo nivel de
replicación. Gastroenterol Hepatol 1984; 7: 461.
25.
Carreño V, Alvarez Chiva V, Porres JC, Hernández‑Guío C,
Hernando L. Patrón serológico de respuesta al virus B de la hepatitis
en el personal sanitario. Gastroenterol Hepatol 1984; 7: 57-60.
26.
Alvarez V, Carreño V,
Plaza JJ, Mora I, Hernando L. Infección por virus de hepatitis en el
transplante renal. Estudio prospectivo. Nefrología 1984; 4: 313-317.
27.
Quiroga JA, Gonzalez O, Carreño
V, Mora I, Porres JC, Gutiez J, Hernández‑Guío C. Radioimmunoassay
for detecting hepatitis B core antigen in serum from patients with chronic
hepatitis B infection. Clin
Chem 1985; 31: 831-834.
28.
Mora I, Porres JC, Carreño V. Receptores
frente a albúmina humana polimerizada (RAHP): nuevos aspectos de la
infección por el virus B de la hepatitis (VBH). Rev
Clin Esp 1985; 176: 1-4.
29.
Carreño V, Mora I, Escuin F, Sánchez Sicilia L, Alvarez V, Casado
S, Alcázar JM, Hernando L, Porres JC, Carrasco JL, Lardinois R. Vaccination
against hepatitis B in renal
dialysis units: short or normal vaccination schedule?. Clin
Nephrol 1985; 24: 215-220.
30.
Salata H, Cortés JM, Enriquez de Salamanca R, Oliva H, Castro A, Kusak
E, Carreño V, Hernández-Guío C.
Porphyria cutanea tarda and hepatocellular carcinoma. Frequency
of ocurrence and related factors. J
Hepatol 1985; 1: 477-487.
31.
Carreño V. Marcadores de replicación viral; su
significado.
Actualizaciones en Medicina Digestiva. Ed. Garsi 1986; 129-133.
32.
Mora I, Carreño V, Porres
JC, Gutiez J, Hernández‑Guío C. Relación entre la presencia de
receptores frente a albúmina humana polimerizada (RAHP) y el nivel de replicación
viral en la infección crónica por el virus B de la hepatitis (VBH). Rev
Clin Esp 1986; 178: 278-282.
33.
Bartolomé J, Castillo I, Carreño
V, Mora I, Gutiez J, Porres JC, Hernández‑Guío C. Determinación
del DNA del virus B de la hepatitis (VBH‑DNA) en portadores crónicos de
AgHBs: relación con otros marcadores de replicación viral. Rev
Clin Esp 1986; 178: 432-435.
34.
Mora I, Porres JC, Hernández‑Guío C, Gutiez J, Carreño
V. Hemagglutination and immunofluorescence studies on polymerized human
serum albumin binding activity in chronic hepatitis B virus infection. Hepatology
1986; 6: 14-19.
35.
Carreño V, Bartolomé J. Progresos en el conocimiento de
la hepatitis por virus B: aporte de la biología molecular. Rev
Clin Esp 1986; 178: 238-239.
36.
Mora I, Porres JC, Bartolomé J, Hernández-Guio C, Gutiez J, Carreño
V. Receptors for polymerized human serum albumin and other hepatitis B
virus markers during acute hepatitis B; predictive value of the outcome of the
disease. Hepato-Gastroenterol
1986; 33: 250-254.
37.
Quiroga JA, Carreño V,
Porres JC, Mora I, Gutiez J, Hernández-Guío C. Comparación entre la
determinación de antígeno del core del virus B de la hepatitis (AgHBc) y
actividad DNA polimerasa como marcadores de replicación vírica.
Gastroenterol Hepatol 1986; 9: 363-366.
38.
Carreño V, Gutiez J, Mora I, Porres JC, Hernández-Guío C.
Estudio de poblaciones linfocitarias en pacientes con
hepatitis por virus B: relación con otras etiologías. Rev
Esp Enf Ap Dig 1986; 70: 493-496.
39.
Mora I, Porres JC, Bartolomé J, Quiroga JA, Gutiez J, Hernández-Guío
C, Bas C, Carreño V. Changes of
hepatitis B virus (HBV) markers during prolonged recombinant interferon
alpha-2A treatment of chronic HBV infection. J Hepatol 1987; 4: 29-36.
40.
Mora I, Carreño V, Porres
JC, Gutiez J, Hernández-Guío C. Hepatitis B surface
antigen/IgM complexes:
relation to receptors for polymerized human serum albumin, hepatitis B virus
(HBV)
DNA polymerase activity and HBV markers. Acta
Virologica 1987; 31: 116-125.
41.
Hernández-Guío C, Carreño V,
Porres JC, Mora I. Hepatitis no-A, no-B. Rev
Clin Esp 1987; 180: 100-103.
42.
Quiroga JA, Bartolomé J, Porres JC, Mora I, Gutiez J, Hernández-Guío
C, Carreño V. Identification of
different degrees of hepatitis B virus (HBV) replicaction by serological
(HBV-DNAp,
HBcAg and HBV-DNA) and histological (HBcAg) methods. Liver
1987; 7: 169-175.
43.
Mora I, Porres JC, Carreño V.
Niveles mínimos de receptores para albúmnia humana polimerizada en la vacuna
antihepatitis B derivada de plasma. Rev
Clin Esp 1987; 181: 172.
44.
Quiroga JA, Bartolomé J, Carreño
V, Mora I, Porres JC, Gutiez J, Hernández-Guío C. Detección del
anticuerpo de clase IgM contra el antígeno del core del virus B de la
hepatitis en pacientes con infección crónica. Rev
Clin Esp 1987; 181: 351-354.
45.
Carreño
V,
Mora I. Combination of recombinant interferons alpha and gamma in treatment of
chronic hepatitis B. Lancet 1987; ii: 1086.
46.
Carreño V, Porres JC, Mora I, Gutiez J, Quiroga JA, Ramon y Cajal
S, Oliva H, Compernolle C, Bartolomé J. A controlled study of treatment with
recombinant interferon alpha in chronic hepatitis B virus infection: induction
and maintenance schedules. Antiviral Res 1987; 8: 125-137.
47.
Mora I, Porres JC, Carreño V.
Receptors for polymerized human serum albumin in plasma derived hepatitis B
vaccines. Vaccine
1987; 5: 279-282.
48.
La Banda F, Carreño V.
Tratamiento de la hepatitis crónica B. Gastroenterol Hepatol 1987; 10 (supl.1):
48-54.
49.
Inglada L, Porres JC, La Banda F, Mora I, Carreño
V. Anti-IFN-alpha titres during interferon
therapy. Lancet 1987; ii: 1521.
50.
Carreño V, Porres JC, Mora I, Bartolomé J, Bas C, Gutiez J, Cortés
J, Hernández-Guío C. Prolonged (6 months) treatment of chronic hepatitis B
virus infection with recombinant leukocyte A interferon. Liver 1987; 7:
325-332.
51.
Bas C, Bartolomé J, Mora I, La Banda F, Porres JC, Hernández-Guío C,
Carreño V. Prevalence of
HBV-DNA
among anti-HD positive patients. En: The hepatitis Delta virus and its
infection, M. Rizzetto, J.L. Gerin, R.H. Purcell eds., Alan R. Liss ed., New
York, NY. 1987; p 327-328.
52.
De Torres M, Bas C, Bartolomé J, Porres JC, Hernández-Guío C, Carreño
V. Liver membrane antibodies and delta
superinfection. En: The hepatitis
Delta virus and its infection, M. Rizzetto, J.L. Gerin, R.H. Purcell eds.,
Alan R. Liss ed., New York, NY. 1987; p 335.
53.
Carreño V, La Banda F, Quiroga JA, Bartolomé J, Mora I. Terapia
antiviral de la hepatitis crónica por virus B. En: Avances en Gastroenterología,
M. Díaz-Rubio ed., Arán Ediciones S.A., Madrid. 1987; p 287-298.
54.
De Torres M, Carreño V,
Bartolomé J, Porres JC, Bas C, Quiroga JA, Mora I. Liver membrane antibodies
in chronic delta hepatitis. Digestion 1987; 38: 171-177.
55.
Quiroga JA, Mora I, Carreño V,
Herrera MI, Porres JC, Gerlich WH. Inhibition
of albumin binding to hepatitis B virions by monoclonal antibody to the preS2
domain of the viral envelope. Digestion
1987; 38: 212-220.
56.
Bas C, Bartolomé J, La Banda F, Porres JC, Quiroga JA, Mora I, Hernández-Guío C, Carreño V.
Infección por virus D de la hepatitis en portadores crónicos del virus B de
la hepatitis: Relación con el sistema HBe. An
Med Intern 1987; 4: 583-586.
57.
La Banda F, Carreño V.
Tratamiento de las hepatitis crónicas producidas por el virus B, delta y
No-A, No-B. Bol Soc Gal Pato Digest 1987; 10: 15-30.
58.
Porres JC, Mora I, Gutiez J, Bartolomé J, Quiroga JA, Bas C,
Compernolle C, Ordi J, Chocarro A, Carreño
V. Antiviral effect of recombinant gamma interferon in chronic hepatitis B
virus infection: A pilot study. Hepato-Gastroenterol
1988; 35: 5-9.
59.
La Banda F, Ruiz-Moreno M, Carreño
V, Bartolomé J, Gutiez J, Ramón y Cajal S, Moreno A, Mora I, Porres JC. Recombinant
a2-interferon
treatment in children with chronic hepatitis B. Lancet 1988; i: 250.
60.
Bas C, Bartolomé J, La Banda F, Porres JC, Quiroga JA, Mora I, Carreño
V. Assessment of hepatitis B Virus DNA levels in chronic HBsAg carriers
with or without hepatitis delta virus superinfection. J Hepatol 1988; 6:
208-213.
61.
Ibarra MZ, Mora I, Quiroga JA, Bartolomé J, La Banda F, Porres JC, Carreño
V. IgG and IgM auto-antiidiotype antibodies against antibody to HBsAg in
chronic hepatitis B. Hepatology 1988; 8: 775-780.
62.
Bartolomé J, Castillo I, Mora I, Gutiez J, Porres JC, Carreño
V. Different levels of hepatitis B virus replication among hepatitis B e
antigen positive chronic carriers. Acta
Virol 1988; 32: 193-197.
63.
Bartolomé J, Castillo I, Bas C, Mora I, Porres JC, Carreño
V. Detección del DNA del virus B de la hepatitis en biopsias hepáticas
de portadores crónicos de AgHBs. Rev
Clin Esp 1988; 183: 67-70.
64.
Gómez C, La Banda F, Porres JC, Mora I, Andrés A, Bartolomé J,
Quiroga JA, Gutiez J, Castillo I, Bas C, Armenteros E, Ibarra MZ, Carreño
V. Combined recombinant alpha and gamma interferon treatment of chronic
hepatitis B virus infection. En: Viral Hepatitis and Liver Diseases, Alan R.
Liss ed., New York, NY. 1988; 872-874.
65.
Quiroga JA, Mora I, Porres JC, Carreño
V. Elevation of 2',5'-Oligoadenylate synthetase activity and
HLA-I
associated ß2-microglobulin in response to recombinant interferon gamma
administration in chronic HBeAg positive hepatitis. J
Interferon Res 1988; 8: 755-763.
66.
Porres JC, Carreño V, Mora
I, Gutiez J, Moreno A, Ramón y Cajal S, Marrón JA, Bartolomé J. Different
doses of recombinant interferon alpha in the treatment of chronic hepatitis B
patients without antibodies against the human immunodeficiency virus. Hepato-Gastroenterol
1988; 35: 300-303.
67.
Carreño V, Quiroga JA, Bartolomé J. Hepatitis: problemas
pendientes. Bol Fund Jiménez Díaz 1988; 12: 36-37.
68.
Carreño V, Castillo I, Mora I. Actualidad en el estudio de los
marcadores del virus del SIDA. Bol Fund Jiménez Díaz. 1988; 12: 105-107.
69.
Ruiz-Moreno M, García-Aguado J, Carreño
V, Alvarez Sala L, Rincón P, López-Linares M, Bas C. Prevalencia de
hepatitis por virus A, B y D en niños. An Esp Pediatr 1988; 29: 357-362.
70.
Castillo I, Carreño V,
Bartolomé J, Porres JC, Mora I, Herrera MI. Virus-like
particles associated with reverse transcriptase activity in acute sporadic
Non-A, Non-B hepatitis. Digestion 1989; 42: 7-15.
71.
Porres JC, Carreño V,
Bartolomé J, Gutiez J, Castillo I. A dynamic study of the intrafamilial
spread of hepatitis B virus infection: relation with the viral replication. J
Med Virol 1989; 28: 237-242.
72.
Ruiz-Moreno M, Camps T, García J, Porres JC, Oliva H, Bartolomé J, Carreño
V. Serological and histological follow-up of chronic hepatitis B
infection.
Arch Dis Child 1989; 64: 1165-1169.
73.
Porres JC, Carreño V,
Ruiz-Moreno M, Marrón JA, Bartolomé J. Interferon antibodies in patients
with chronic HBV infection treated with recombinant interferon. J Hepatol
1989; 8: 351-357.
74.
Ibarra MZ, Mora I, Bartolomé J, Porres JC, Carreño
V. Detection of proteins encoded by the pre-S region of hepatitis B virus
in the sera of HBsAg carriers: relation to viral replication. Liver
1989; 9: 153-158.
75.
Porres JC, Carreño V,
Bartolomé J, Moreno A, Galiana F, Quiroga JA. Treatment
of chronic delta infection with recombinant human interferon alpha 2c at high
doses. J Hepatol 1989; 9: 338-344.
76.
Saldanha J, di Blas F, Bas C, Velosa J, Ramalho FM, di Marco V, Mora I,
Carreiro de Moura M, Carreño V,
Craxi A, Thomas HC, Monjardino J. Detection of hepatitis delta virus RNA in
chronic liver disease. J Hepatol 1989; 9: 23-28.
77.
Moraleda G, Bartolomé J, Madejón A, Martinez MG, Moreno E, Loinaz C,
Gómez M, Carreño V.
Influence of the positivity to HBV-DNA in serum, liver and peripheral
mononuclear cells in the risk of HBV allograft infection after liver
transplantation in HBsAg-positive recipients. Traspl Organs Tiss. 1989; 1:
19-22.
78.
Moreno A, Ramón y Cajal S, Marazuela M, Carreño
V, Milicua JM, Cerezo E, Cuesta C, Oliva H. Sanded nuclei in delta
hepatitis. Liver
1989; 9: 367-371.
79.
Quiroga JA, Carreño V.
Interferon and hepatitis B vaccine in haemodialysis patients. Lancet 1989; i:
1264.
80.
Ruiz-Moreno M, Jimenez J, Porres JC, Bartolomé J, Moreno A, Carreño
V. A controlled trial of recombinant interferon alpha in caucasian
children with chronic hepatitis B. Digestion 1990; 45: 26-33.
81.
Bartolomé J, Moraleda G, Castillo I, Martínez MG, Porres JC, Carreño
V. Presence of HBV-DNA in peripheral blood mononuclear cells from
anti-HIV
symtomless carriers. J Hepatol 1990; 10: 186-190.
82.
Castillo I, Bartolomé J, Quiroga JA, Porres JC, Carreño
V. Detection of HBeAg/anti-HBe immune complexes in the reactivation of
hepatitis B virus replication among anti-HBe chronic carriers. Liver 1990; 10:
79-84.
83.
Ibarra MZ, Porres JC, Bartolomé J, Escudero M, Quiroga JA, Carreño
V. Changes in anti-idiotype antibodies against
anti-HBs during recombinant
interferon treatment of chronic hepatitis B. J Interferon Res 1990; 10:
367-373.
84.
Porres JC, Hernández-Guío C, Carreño
V. Avances realizados en el tratamiento de la hepatitis crónica por virus
C. Rev Esp Enf Digest 1990; 77: 437-438.
85.
Quiroga JA, Castillo I, Porres JC, Casado S, Sáez-Royuela F, Martínez
MG, Gómez M, Inglada L, Sánchez-Sicilia
L, Mora I, Galiana F, Barril G, Carreño
V. Recombinant gamma interferon as adjuvant to hepatitis B vaccine in
hemodialysis patients. Hepatology 1990; 12: 661-663.
86.
Carreño V, Mora I, Quiroga JA, Bartolomé J, Bas C, Castillo I.
Aspectos celulares y moleculares de la hepatitis vírica. En: Nuevas
tendencias en Hepatología, M Cascales Ed., Madrid, CSIC. 1990.
87.
Bartolomé J, Moraleda G, Molina J, Domínguez F, Porres JC, Carreño
V. Hepatitis B virus DNA in liver and peripheral blood mononuclear cells
during reduction in virus replication. Gastroenterology 1990; 99: 1745-1750.
88.
Bartolomé J, Moraleda G, Ruíz-Moreno M, Porres JC, Carreño
V. Hepatitis B virus DNA patterns in the liver of children with chronic
hepatitis B. J Med Virol 1990; 31: 195-199.
89.
Gómez Rubio M, Porres JC, Castillo I, Quiroga JA, Moreno A, Carreño
V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant
a-interferon
in comparison with a control group.
J Hepatol 1990; 11 (S1): s63-s67.
90.
Carreño V, Quiroga JA. Vacunas frente al virus de la hepatitis
B.
Problemas pendientes. Rev.
Clin. Esp. 1990; 187: 247-248.
91.
Moraleda G, Bartolomé J, Martínez MG, Porres JC, Carreño
V. Influence of hepatitis delta virus replication in the presence of
hepatitis B virus DNA in peripheral blood mononuclear cells. Hepatology 1990;
12: 1290-1294.
92.
Madejón A, Castillo I, Bartolomé J, Melero M, Campillo ML, Porres JC,
Moreno A, Carreño V. Detection of
HDV-RNA by PCR in serum of patients with chronic HDV infection. J Hepatol
1990; 11: 381-384.
93.
Carreño V, Saez-Royuela F, Gómez Rubio M. Use of recombinant
interferon in the treatment of chronic non-A, non-B hepatitis: Results of two
controlled trials. Proceedings of the IV International Symposium on Viral
Hepatitis. Mediscript Ed. London (UK). (1990);
103-106.
94.
Carreño V, Quiroga JA. Epidemiología y prevención de la
hepatitis vírica en pacientes hemodializados. Gastroenterol
Hepatol 1990; 13: 517-518.
95.
Martínez MG, Castillo I, Quiroga JA, Porres JC, Carreño
V. Detection of serum inhibitory factor for lymphocyte stimulation in
chronic viral hepatitis: relationship with the replication level. Liver
1991; 11: 48-52.
96.
Ruiz-Moreno M, Rúa MJ, Carreño
V, Quiroga JA, Manns M, Meyer zum Büschenfelde KH. Autoimmune
chronic hepatitis type 2 manifested during interferon therapy in children. J
Hepatol 1991; 12: 265-266.
97.
Saez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F,
Carreño V. High doses of
recombinant alpha interferon or gamma interferon for chronic hepatitis C: a
randomized controlled trial. Hepatology 1991; 13: 327-331.
98.
Castillo I, Bartolomé J, Madejón A, Melero M, Porres JC, Carreño
V. Hepatitis delta virus RNA detection in chronic HBsAg carriers with and
without HIV infection. Digestion 1991; 48: 149-156.
99.
Ruiz-Moreno M, Rua MJ, Molina J, Moraleda G, Moreno A, García-Aguado
J, Carreño V. Prospective
randomized controlled trial of alpha interferon in children with chronic
hepatitis B. Hepatology 1991; 13: 1035-1039.
100.
Carreño V, Quiroga JA. Treatment
of chronic hepatitis B with alpha interferon: Present and future. J Hepatol
1991; 13: S2.
101.
Quiroga JA, Campillo ML, Castillo I, Bartolomé J, Porres JC, Carreño
V. IgM antibody to hepatitis C virus in acute and chronic hepatitis
C.
Hepatology 1991; 14: 38-43.
102.
Diez A, Quiroga JA, Melero M, Moraleda G, Castillo I, Porres JC, Carreño
V. Detection of antibody to calmodulin in chronic
viral hepatitis: lack
of correlation with virus replication and hepatocellular damage. Digestion
1991; 49: 125-133.
103.
Carreño V, Porres JC, Ruiz-Moreno M, Gutiez J, Bartolomé J.
Estudio controlado de tratamiento con interferon alfa recombinante en la
hepatitis crónica por virus B en la infancia. Rev
Esp Enf Digest 1991; 79: 24-28.
104.
Escudero MM, Quiroga JA, Bartolomé J, Carreño
V. Analysis of serum pre-S antigens in chronic hepatitis B virus infection
in relation to the expression pattern of hepatitis B virus DNA in the liver.
Digestion 1991; 49: 204-211.
105.
Moraleda G, Bartolomé J, Molina J, Castillo I, Carreño
V. Analysis of hepatitis B virus DNA, liver disease and influence of
antibody to hepatitis C virus in anti-HBe chronic carriers. Liver
1991; 11: 352-357.
106.
Porres JC, Carreño V,
Moreno A, Bartolomé J. Reactivación del virus B de la hepatitis en
portadores crónicos con anti-HBe. Rev
Clin Esp 1991; 189: 68-72.
107.
Thomas HC, Dusheiko GM, Lok ASF, Farrell GC, Williams SJ, Cooksley WGE,
Pérez V, Tanno H, Carreño V,
Ryff JC. Comparative study of three doses of interferon alpha-2A in chronic
active hepatitis B. En: Viral Hepatitis and Liver Disease. F.B. Hollinger,
S.M. Lemon, H. Margolis, eds. Williams and Wilkins, Baltimore, MD, 1991: 641-642.
108.
Campillo ML, Quiroga JA, Bartolomé J, Moraleda G, Castillo I, Carreño
V. Protein composition of hepatitis B virus e antigen in the natural
course of the disease and following interferon therapy. J Clin Microbiol 1992;
30: 1256-1261.
109.
Carreño V, Tapia L, Ryff JC, Quiroga JA, Castillo I. Treatment of
chronic hepatitis C by continuous subcutaneous infusion of interferon-alpha. J
Med Virol 1992; 37: 215-219.
110.
Ortiz A, Quiroga JA, García Delgado R, Carreño
V, Caramelo C. Virus de la hepatitis C y
crioglobulinemia. Rev Clín Esp
1992; 190: 157.
111.
Ruiz-Moreno M, Rúa MJ, Castillo I, García-Novo MD, Santos M, Navas S,
Carreño V. Treatment of children
with chronic hepatitis C with recombinant alpha interferon: a pilot study.
Hepatology 1992; 16: 882-885.
112.
Castillo I, Bartolomé J, Quiroga JA, Carreño
V. Comparison of several PCR procedures for detection of HCV RNA using
different regions of the HCV genome. J Virol Methods 1992; 38: 71-80.
113.
Caramelo C, Carreño V,
González-Parra E, Quiroga JA, Garrón MP, Marriott E, Ortíz A, Galera A, López
MD, Porres JC. Positive
ELISA-2 is pathologically relevant in ELISA-1-negative patients on
hemodialysis. Nephron 1992; 61: 474.
114.
Marriott E, Quiroga JA, Carreño
V. Re-Treatment of chronic hepatitis C with
alpha-interferon. J Infect Dis
1992; 166: 1200-1.
115.
Ruíz-Moreno M, Carreño V,
Rúa MJ, Cotonat T, Serrano B, Santos M,
Marriott E. Increase in triglicerides during alpha interferon treatment
of chronic viral hepatitis. J Hepatol 1992; 16: 384.
116.
Carreño V, Castillo I, Molina J, Porres JC, Bartolomé J. Long-term
follow-up of hepatitis B chronic carriers who responded to interferon therapy.
J Hepatol 1992; 15: 102-106.
117.
Quiroga JA, Bosch O, Gonzalez R, Marriott E, Castillo I, Bartolomé J, Carreño
V. Immunoglobulin M antibody to hepatitis C virus during interferon
therapy for chronic hepatitis C. Gastroenterology 1992; 103: 1285-1289.
118.
Ruiz-Moreno M, Rúa MJ, Moraleda G, Guardia L, Moreno A, Carreño
V. Treatment with interferon gamma versus interferons alfa and gamma in
children with chronic hepatitis B. Pediatrics 1992; 90: 254-258.
119.
Molina J, Bartolomé J, Moraleda G, Ruiz-Moreno M, Rúa MJ, Moreno A, Carreño
V. Persistence of hepatitis B virus DNA after eduction of viral
replication in serum and liver. J Med Virol 1992; 38: 11-15.
120.
Bosch O, Tapia L, Quiroga JA, Carreño
V. An escalating dose regime of recombinant
interpheron-alpha 2A in the
treatment of chronic hepatitis C. J Hepatol 1993; 17: 146-149.
121.
Bartolomé J, Castillo I, Quiroga JA, Navas S, Carreño
V. Detection of hepatitis C virus RNA in serum and peripheral blood
mononuclear cells. J Hepatol 1993; 17: s90-s93.
122.
Moreno A, Martinez CJ, Carreño
V. Liver biopsy and the etiologic diagnosis of chronic hepatitis. J
Hepatol 1993; 17: s112-s115.
123.
Moreno-González E, Loinaz C, García I, Lumbreras C, Gómez R,
Moraleda G, Pinto IG, Colina F, Jiménez C, Carreño
V, Bercedo J, Ibañez J, Alberti N, Maffettone
V. Liver transplantation in chronic viral B and C hepatitis.
124.
Carreño V, Marriott E, Quiroga JA. Other
approaches to the treatment of chronic viral hepatitis. J Hepatol 1993; 17:
s127-s129.
125.
Madejón A, Castillo I, Cotonat T, Carreño
V. Significance of low HDV replication levels during the natural history
of HDV infection. J Hepatol 1993; 17: s157-s160.
126.
Navas S, Castillo I, Carreño V.
Detection of plus and minus HCV-RNA in normal liver of anti-HCV positive
patients. Lancet
1993; 341: 904-905.
127.
Carreño V. Ultimos avances en hepatología. Hepatol
Clin 1993; 1: 71-82.
128.
Carreño V, Moreno A, Galiana F, Bartolomé J. Alpha and gamma
interferon versus alpha interferon alone in chronic hepatitis B. A randomized
controlled trial. J Hepatol 1993; 17: 321-325.
129.
Marriott E, Navas S, del Romero J, García S, Castillo I, Quiroga JA, Carreño
V. Treatment with recombinant
alpha-interferon of chronic hepatitis C in anti-HIV positive patients. J Med Virol 1993; 40: 107-111.
130.
Carreño V. Ultimos avances en hepatología. Hepatol ClIn 1993;
1:
149-162.
131.
Ruiz-Moreno M, García R, Rúa MJ, Serrano B, Moraleda G, Feijoo E,
Bartolomé J, Ortiz F, Castillo I, Carreño
V. Levamisole and interferon in children with chronic hepatitis
B.
Hepatology 1993; 18: 264-269.
132. Carreño V, Quiroga JA. Ultimos avances en hepatología. Hepatol Clin 1993; 1: 224-244.
133.
Bosch O, Moraleda G, Castillo I, Carreño
V. Treatment of chronic hepatitis B with recombinant interferon alpha
versus recombinant interferon alpha plus levamisole. J Hepatol 1993; 19:
437-441.
134.
Martín J, Bosch O, Moraleda G, Bartolomé J, Quiroga JA, Carreño
V. Pilot study of recombinant human
granulocyte-macrophage colony-stimulating
factor in the treatment of chronic hepatitis B. Hepatology 1993; 18: 775-780.
135.
Caramelo C, Ortiz A, Aguilera B, Porres JC, Navas S, Marriott E,
Alberola ML, Alamo C, Galera A, Garron MP, González-Parra E, Fernández de
Gabriel MV, Oliva H, Carreño V.
Liver disease patterns in hemodialysis patients with antibodies to hepatitis C
virus. Am
J Kidney Dis 1993; 22: 822-828.
136.
Carreño V. Virus C de la hepatitis: vacunación y tratamiento
problemáticos. Rev
Clin Esp 1993; 192: 155-156.
137.
Carreño V, Hernández-Guío C, Bartolomé J, Quiroga JA. Cambios
en los niveles séricos de la actividad 2',5'-oligoadenilato sintetasa,
ß2-microglobulina
y neopterina durante el aclaramiento del virus B de la hepatitis con o sin
agudización en las transaminasas. Rev
Esp Enf Digest 1993; 83: 169-175.
138.
Carreño V, Bartolomé J, Castillo I. Ultimos avances en hepatología.
Hepatol Clin 1993; 1: 335-354.
139.
Alberola ML, Caramelo C, Navas S, Garrón MP, Aguilera B, Carreño
V, Bermejillo T, Reyero R, Galera A, Marriott E, Ortiz A, Alcázar R,
Alamo C, Porres JC. Infección
por virus C de la hepatitis en pacientes en hemodiálisis y en receptores de
transplante renal. Hepatol Clin 1993; 1: 185-193.
140.
Ortiz A, Quiroga JA, García Delgado R, Carreño
V, Caramelo C. Virus de la hepatitis C y
crioglobulinemia. Rev Clín Esp
1993; 192: 157.
141.
Carreño V, Bartolomé J, Castillo I. Long-term effect of
interferon therapy in chronic hepatitis B. J Hepatol 1994; 20: 431-435.
142.
Carreño V, Pardo M. Tratamiento de la hepatitis crónica por VBH y
VDH. Rev.
And Patol Digest 1994; 17: 17-21.
143.
Caramelo C, Navas S, Alberola ML, Bermejillo T, Reyero A, Carreño
V. Evidence against transmission of hepatitis C virus through hemodialysis
ultrafiltrate and peritoneal fluid. Nephron
1994; 66: 470-473.
144.
Carreño V. Ultimos avances en hepatología. Hepatol
Clin 1994; 2: 47-74.
145.
Madejón A, Cotonat T, Bartolomé J, Castillo I, Carreño
V. Treatment of chronic hepatitis D virus infection with low and high
doses of interferon-alpha 2a: Utility of polymerase chain reaction in
monitoring antiviral response. Hepatology 1994; 19: 1331-1336.
146.
Castillo I, Bartolomé J, Navas S, Gonzalez S, Herrero M, Carreño
V. Virological and biochemical long-term
follow-up of patients with
chronic hepatitis C treated with interferon. Hepatology 1994; 19: 1342-1346.
147.
Pardo M, Cotonat T, Herrero M, Marriott E, Artillo S, Quiroga JA, Carreño
V. Retreatment of chronic hepatitis C virus
infection. Lancet 1994; 343:
1568-1569.
148.
Navas S, Castillo I, Bartolomé J, Marriott E, Herrero M, Carreño
V. Positive and negative hepatitis C virus RNA strands in
serum, liver and
peripheral blood mononuclear cells in anti-HCV patients: Relation with the
liver lesion. J Hepatol 1994; 21: 182-186.
149.
Pardo, Carreño V. Lack of
efficacy of inosine pranobex in the treatment of chronic hepatitis C. J
Hepatol 1994; 21: 278.
150.
López-Alcorocho JM, Moraleda G, Bartolomé J, Castillo I, Cotonat T,
Aguilar J, Ortega E, Pons JA, Salmerón J, Vázquez-Iglesias JL, Carreño
V. Analysis of hepatitis B precore region in serum and liver of chronic
hepatitis B virus carriers. J Hepatol 1994; 21: 353-360.
151.
Quiroga JA, Herrero M, Castillo I, Navas S, Pardo M, Carreño
V. Long-term follow-up study of serum IgM antibody to hepatitis C virus
(HCV),
HCV replication and liver disease outcome in chronic hepatitis C. J Infect Dis
1994; 170: 669-673.
152.
Carreño V, Quiroga JA. Hepatitis viral
aguda. En: Tratado de
Medicina Interna, Sección XI, Capítulo 5. M. Díaz Rubio, D. Espinós Eds.
Editorial Panamericana, Madrid, 1994; 1384-1396
153.
Krogsgaards K, Bindslev N, Christensen E, Craxi A, Schlichting P,
Schalm S, Carreño
V, Trepo C, Gerken G, Thomas HC, Andersen PK, Ring-Larsen H and the
European Concerted Action on Viral Hepatitis (Eurohep). The treatment effect
of alpha interferon in chronic hepatitis B is independent of pre-treatment
variables. Results based on individual patient data from 10 clinical
controlled trials. J
Hepatol 1994; 21: 646-655.
154.
Carreño V, Bartolomé J, Castillo I. Ultimos avances en hepatología.
Hepatol
Clin 1994; 2: 131-160.
155.
Quiroga JA, Martín J, Pernas M, Pardo M, Herrero M, Castillo I,
Bartolomé J, Carreño V. Evidence
of Subtype-Specific Antibodies to Antigenic Epitopes in the NS5 Region of
Hepatitis C Virus in the Circulation of Patients with Chronic Hepatitis C.
Clin Diag Lab Immunol 1994; 1: 545-551.
156.
González Parra E, Bermejillo T, Martín J, Aguilera B, Ortiz A, Fernández
de Gabriel MV, Carreño V,
Caramelo C. Niveles de interferón recombinante humano alfa 2b en pacientes en
hemodiálisis. Nefrología
1994; 14: 207-210
157.
Martín J, Quiroga JA, Bosch O, Carreño
V. Changes in cytokine production during therapy with
granulocyte-macrophage colony-stimulating factor in patients with chronic hepatitis B. Hepatology
1994; 20: 1156-1161.
158.
Carreño V. Ultimos avances en hepatología. Hepatol
Clin 1994; 2: 201-228.
159.
Quiroga JA, Martín J, Pardo M, Carreño
V. Serum levels of soluble immune factors and pathogenesis of chronic
hepatitis C, and their relation to therapeutic response to alpha-interferon.
Dig Dis Sci 1994; 39: 2485-2496.
160.
Carreño V, Bartolomé J, Madejón A. Hepatitis delta virus
infection: Molecular biology and treatment. Dig Dis 1994; 12: 265-275.
161.
Carreño V, Castillo I, Quiroga JA. Ultimos avances en hepatología.
Hepatol
Clin 1994; 2: 275-308.
162.
Thomas HC, Lok ASF, Carreño V,
Farrell G, Tanno H, Pérez V, Dusheiko GM, Cooksley G, Ryff JC and the
International Hepatitis Trial Group. Comparative study of three doses of
interferon-alpha 2a in chronic active hepatitis B. J Viral Hepatitis 1994; 1:
139-148.
163.
Pernas M, Bartolomé J, Castillo I, Quiroga JA, Pardo M, Carreño
V. Sequence of non-structural regions 3 and 5 of hepatitis C virus genomes
from Spanish patients: existence of a predominant variant related to type 1b. J
Gen Virol 1995; 76: 415-420.
164.
Navas S, Bosch O, Castillo I, Marriott E, Carreño
V. Porphyria cutanea tarda and hepatitis C and B viruses
infection: A
retrospective study. Hepatology
1995; 21: 279-284.
165.
González S, Navas S, Madejón A, Bartolomé J, Castillo I, Moraleda G,
Martín J, Marriott E, Herrero M, Carreño
V. Hepatitis B and D genomes in hepatitis B surface antigen negative
patients with chronic hepatitis C. J Med Virol 1995; 45: 168-173.
166.
Bartolomé J, Madejón A, Carreño
V. Ribozymes: structure, characteristics and use as potential antiviral
agents. J Hepatol 1995; 22: s57-s64.
167.
Navas S, Carreño V.
Semiquantification by AmplicorTM assay of hepatitis C virus genome
during therapy. J Hepatol 1995; 22: s115-s117.
168.
Carreño V, Quiroga JA. Biologic
response modifiers in chronic hepatitis C. J Hepatol 1995; 22: s122-s126.
169.
Carreño V, Quiroga JA, Castillo I. Ultimos avances en hepatología.
Hepatol
Clin. 1995; 3: 39-66.
170.
Pardo M, Castillo I, Navas S, Carreño
V. Treatment of chronic hepatitis C with cirrhosis with recombinant human
granulocyte colony-stimulating factor plus recombinant interferon alpha. J Med
Virol 1995; 45: 439-444.
171.
Ruíz-Moreno M, Camps T, Jiménez J, López R, Castillo I, Bartolomé
J, Carreño V. Factors predictive
of response to interferon therapy in children with chronic hepatitis B. J
Hepatol 1995; 22: 540-544.
172.
Carreño V. Castillo I. Ultimos avances en hepatología. Hepatol
Clin 1995; 3: 91-118.
173.
Castillo I, Bartolomé J, Ruiz-Moreno M, Sánchez V, Navas S, Carreño
V. Hepatitis C virus genotypes in serum and liver of children with chronic
hepatitis C. Pediatric Res 1995; 38: 618-620.
174.
Pardo M, Marriott E, Moliner MC, Quiroga JA, Carreño
V. Risk and benefits of interferon-alpha in the treatment of
hepatitis.
Drug Safety 1995; 13: 304-316.
175.
Quiroga JA, van Binsbergen J, Wang CY, Pardo M, Navas S, Trines Ch,
Herrero M, Carreño V.
Immunoglobulin M antibody to hepatitis C virus core antigen: Correlations with
viral replication, histological activity and liver disease outcome. Hepatology
1995; 22: 1635-1640.
176.
Carreño V, Bartolomé J, Castillo I. Ultimos avances en hepatología.
Hepatol
Clin 1995; 3: 223-240.
177.
López-Alcorocho JM, Cabrerizo M, Bartolomé J, Cotonat T, Carreño
V. Analysis of hepatitis B virus precore variants in hepatitis B e
antibody-positive patients treated with prednisone plus interferon. J Viral
Hepatitis 1995; 2: 279-284.
178.
Quiroga JA, Pardo M, Navas S, Martín J, Carreño
V. Patterns of immune responses to the
host-encoded GOR and hepatitis C
virus core-derived epitopes with relation to hepatitis C viremia, genotypes
and liver disease severity. J Infect Dis 1996; 173: 300-305.
179.
Martín J, Navas S, Quiroga JA, Carreño
V. Recombinant human granulocyte
colony-stimulating factor reduces
hepatitis C virus replication in mononuclear cells from chronic hepatitis C
patients. Cytokine
1996; 8: 313-317.
180.
Carreño V, Parra A, Navas S, Quiroga JA. Granulocyte-Macrophage
Colony-Stimulating Factor as Adjuvant Therapy for Interferon-a
Treatment of Chronic Hepatitis C. Cytokine 1996; 8: 318-322.
181.
Carreño V. Ultimos avances en hepatología. Hepatol Clin 1996;
4:
47-70.
182.
Carreño V, Quiroga JA. New
and forthcoming therapies for viral hepatitis. J Hepatol 1996; 24 (Suppl. 2):
s74-s76.
183.
Cabrerizo M, Bartolomé J, Ruíz-Moreno M, Otero M, López-Alcorocho
JM, Carreño V. Distribution of
the predominant hepatitis B virus precore variants in hepatitis B e
antigen-positive
children and their effect on treatment response. Pediatric
Res. 1996; 39: 980-984.
184.
Carreño V. Ultimos avances en hepatología. Hepatol
Clin 1996; 4: 125-142.
185.
Quiroga JA, Cotonat T, Castillo I, Carreño
V. Hepatitis E virus seroprevalence in acute viral hepatitis in a
developed country confirmed by supplemental assay. J Med Virol 1996; 50:
16-19.
186.
García-Trevijano ER, López-Alcorocho JM, Quintana M, Hernández F, Carreño
V. HGV in coagulation-factor concentrates. Lancet 1996; 348: 1032.
187.
Madejón A, Carreño V.
Virus delta de la hepatitis. En: Tratado de Hepatología, Tomo I, Sección IV:
Hepatitis Virales, Capítulo 29. J.M. Herrerías, A. Díaz, M. Jiménez Eds.
Sevilla, 1996; 353-364.
188.
Carreño V, Quiroga JA. Tratamiento de las hepatitis crónicas por
virus B y C. Farm Hosp 1996; 20: 324-327.
189.
Caramelo C, Bartolomé J, Albalate M, de Sequera P, Navas S, Bermejillo
T, Oliva H, Marriott E, Ortiz A, Ruiz Tuñón C, Casado S, Carreño
V. Undiagnosed hepatitis C virus infection in hemodialysis
patients: Value
of HCV-RNA and liver enzyme levels. Kidney
Int 1996; 50: 2027-2031.
190.
Navas S, Castillo I, Martín J, Quiroga JA, Bartolomé J, Carreño
V. Concordance of hepatitis C virus typing methods based on restriction
fragment length polymorphism analysis in 5' noncoding region and NS4
serotyping, but not in core PCR or a line probe assay. J Clin Microbiol 1997;
21: 317-321.
191.
Bartolomé J, Quiroga JA, Carreño
V. Ultimos avances en hepatología. Hepatol
Clin 1996; 4: 215-240.
192.
Caramelo C, Albalate M, Bermejillo T, Navas S, Ortiz A, de Sequera P,
Casado S, Carreño V.
Relationships between plasma ferritin and aminotransferase profile in
haemodialysis patients with hepatitis C virus. Nephrol
Dial Transpl 1996; 11: 1792-1796.
193.
Ruíz-Moreno M, Fernández P, Leal A, Bartolomé J, Castillo I, Oliva
H, Carreño V. Pilot interferon
beta trial in children with chronic hepatitis B who had previously not
responded to interferon alpha therapy. Pediatrics 1997; 99: 222-225.
194.
López-Alcorocho JM, Bartolomé J, Cotonat T, Carreño
V. Efficacy of prolonged interferon-alpha treatment in chronic hepatitis B
patients with HBeAb: comparison between 6 and 12 months of therapy. J Viral
Hepatitis 1997; 4 (Suppl. 1): 27-32.
195.
Castro A, Suárez D, Inglada L, Carballo E, Domínguez A, Diago M, Such
J, del Olmo JA, Pérez-Mota A, Pedreira J, Quiroga JA, Carreño
V. Multicenter randomized, controlled study of intramuscular
administration of interferon-ß for the treatment of chronic hepatitis C. J.
Interf Cytok Res 1997; 17: 27-30.
196.
Moreno A, Carreño V, Cano
A, González C. Idiopathic biliary ductopenia in adults without symptoms of
liver disease. N Engl J Med 1997; 336: 835-838.
197.
Castro A, Carballo E, Domínguez A, Diago M, Suárez D, Quiroga JA, Carreño
V. Tolerance and efficacy of subcutaneous
interferon-ß administered for
treatment of chronic hepatitis C. J Interf Cytok Res 1997; 17: 65-67.
198.
Amaro MJ, Bartolomé J, Pardo M, Cotonat T, López-Farré A, Carreño
V. Decreased nitric oxide production in chronic viral hepatitis B and C. J
Med Virol 1997; 51: 326-331.
199.
Fernández M, Quiroga JA, Martín J, Cotonat T, Pardo M, Horisberger MA,
Carreño
V. Impaired interferon induction of the human MxA protein in chronic
hepatitis B virus infection. J Med Virol 1997; 51: 332-337.
200.
López-Alcorocho JM, Millán A, García-Trevijano ER, Bartolomé J, Ruíz-Moreno
M, Otero M, Carreño V. Detection
of hepatitis GB virus type C RNA in serum and liver from children with chronic
viral hepatitis B and C. Hepatology 1997; 25: 1258-1260.
201.
Tomás JF, Rodríguez-Iñigo E, Bartolomé J, Madejón A, Fogeda M,
Oliva H, Moreno A, Fernández-Rañada JM, Carreño
V. Detection Of. hepatitis G virus from serum and liver of a patient with
long-term liver dysfunction after autologous bone marrow transplantation. Bone
Marrow Transplant 1997; 19: 1053-1057.
202.
Martín J, Quiroga JA, Carreño
V. Interleuquina 12: propiedades biológicas y bases para su uso terapéutico
en las infecciones crónicas por los virus B y C de la hepatitis. Hepatol Clin
1997; 5: 31-36.
203.
Carreño V. Ultimos avances en hepatología. Hepatol Clin 1997; 5:
37-60.
204.
de Sequera P, Caramelo C, Navas S, Goicoechea M, Bartolomé J,
Bermejillo T, Albalate M, Ortiz A, Casado S, Carreño
V. Hepatitis aguda por virus C (VHC) en un paciente en hemodiálisis con
anticuerpos positivos: reinfección versus reactivación. Nefrología
1997; 17: 178-180.
205.
Rodríguez-Iñigo E, Bartolomé J, López-Alcorocho JM, Cotonat T,
Oliva H, Carreño V. Activation of
liver disease in healthy hepatitis B surface antigen carriers during
interferon-alpha treatment. J Med Virol 1997; 53: 76-80.
206.
Rodríguez-Iñigo E, Tomás JF, Gómez-García de Soria V, Bartolomé
J, Pinilla I, Amaro MJ, Carreño V,
Fernández-Rañada JM. Hepatitis
C and G virus infection and liver dysfunction after allogeneic bone marrow
transplantation: Results from a prospective study. Blood 1997; 90: 1326-1331.
207.
Madejón A, Fogeda M, Bartolomé J, Pardo M, González C, Cotonat T, Carreño
V. GB virus C RNA in serum, liver, and peripheral blood mononuclear cells
from patients with chronic hepatitis B, C, and D. Gastroenterology 1997; 113:
573-578.
208.
Bartolomé J, Carreño V.
Idiopathic Biliary Ductopenia. N Engl J Med 1997; 337: 280-281.
209.
Pardo M, Carreño V.
Conferencia del consenso del NIH con respecto al control de la hepatitis C.
Hepatol Clin 1997; 5: 61-84.
210.
Navas S, Herrero M, Pernas M, Castillo I, Martín J, Marriott E, Pardo
M, Colucci G, Carreño
V. Tratamiento de la hepatitis crónica C con dosis altas de interferón
alfa. Hepatol Clin 1997; 5: 85-92.
211.
Carreño V, Quiroga JA. Ultimos avances en hepatología. Hepatol
Clin 1997; 5: 93-108.
212.
Cabrerizo M, Bartolomé J, de Sequera P, Caramelo C, Carreño
V. Hepatitis B virus DNA in serum and blood cells of hepatitis B surface
antigen-negative hemodialysis patients and staff. J Am Soc Nephrol 1997; 8:
1443-1147.
213.
Pardo M, Castillo I, Oliva H, Fernández-Flores A, Bárcena R, Antje de
Peuter M, Carreño V. A pilot
study of recombinant interleukin-2 for treatment of chronic hepatitis C.
Hepatology 1997; 26: 1318-1321.
214.
Carreño V, Quiroga JA. Biological
properties of interleukin-12 and its therapeutic use in persistent hepatitis B
virus and hepatitis C virus infection. J Viral Hep 1997; 4 (Suppl.2): 83-86.
215.
Albalate M, García López D, Vázquez A, De Sequera P, Marriott E, Tan
D, Ortiz A, Casado S, Carreño V,
Caramelo C. Concentrated ascitic fluid reinfusion in cirrhotic
patients: A
simplified method. Am
J Kidney Dis 1997; 29: 392-398.
216.
Carreño V, Bartolomé J. Ultimos avances en hepatología. Hepatol
Clin. 1997; 5: 143-154.
217.
Navas S, Martín J, Quiroga JA, Castillo I, Carreño
V. Genetic diversity and tissue compartmentalization of the hepatitis C
virus genome in blood mononuclear cells, liver and serum from chronic
hepatitis C patients. J Virol 1998;72:1640-1646.
218.
Artillo S, Pastore G, Alberti A, Milella M, Santantonio T, Fattovich G,
Giustina G, Ryff JCh, Chanéac M, Bartolomé J, Carreño
V. Double-blind, randomized controlled trial of
interleukin-2 treatment of
chronic hepatitis B. J Med Virol 1998; 54: 167-172.
219.
Martín J, Navas S, Quiroga JA, Colucci G, Pardo M, Carreño
V. Quantitation of hepatitis C virus in liver and peripheral blood
mononuclear cells from patients with chronic hepatitis C virus infection. J
Med Virol 1998; 54: 265-270.
220.
Carreño V, Castillo I, Pardo M, Quiroga JA. Ultimos avances en
hepatología. Hepatol Clin 1997; 5: 189-224.
221.
Ortiz A, de Sequera P, Carreño
V, Caramelo C. Hepatitis B virus infection. N
Engl J Med 1998; 338: 1311.
222.
Gosálvez J, Rodríguez-Iñigo E, Ramiro-Díaz JL, Bartolomé J, Tomás
JF, Oliva H, Carreño V. Relative
quantification and mapping of hepatitis C virus by in situ
hybridization and digital image analysis. Hepatology
1998; 27: 1428-1434.
223.
Carreño V, Quiroga JA. Ultimos avances en hepatología. Hepatol
Clin 1998; 6: 25-34.
224.
Quiroga JA, Martín J, Navas S, Carreño
V. Induction of interleukin-12 production in chronic hepatitis C virus
infection correlates with the hepatocellular damage. J Infect Dis 1998; 178:
247-251.
225.
Martín J, Navas S, Quiroga JA, Pardo M, Carreño
V. Effects of the ribavirin-interferon alpha combination on cultured
peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine
1998; 10: 635-644.
226.
Madejón A, Bartolomé J, Carreño
V. In vitro inhibition of the hepatitis delta virus replication mediated
by interferon and trans-ribozyme or antisense probes. J Hepatol 1998; 29:
385-393.
227.
Goicoechea M, Martín J, de Sequera P, Quiroga JA, Ortiz A, Carreño
V, Caramelo C. Role of
cytokines in the response to erythropoietin in hemodialysis patients. Kidney
Int 1998; 54: 1337-1343.
228.
Carreño V, Quiroga JA. The
role of granulocyte-macrophage colony-stimulating factor in the treatment of
chronic hepatitis C. Hepatol Clin 1998; 6: Suppl. 1: 113-115.
229.
Pardo M, Castillo I, Carreño V.
Mild idiopathic biliary ductopenia: Lack of familial clustering. J Hepatol
1998; 29: 685.
230.
Cabrerizo M, Bartolomé J, Rodríguez-Iñigo E, López-Alcorocho JM,
Cotonat T, Carreño V. Analysis of
the hepatitis B virus precore and ORF-X sequences in patients with antibody to
hepatitis B e antigen with and whithout normal ALT levels. J Med Virol 1998;
56: 294-299.
231.
Krogsgaard K, the Long-term Follow-up Investigator Group and the
European Study Group on Viral Hepatitis (EUROHEP). The
long-term effect of
treatment with interferon-alpha 2a in chronic hepatitis B. J Viral Hepat 1998;
5: 389-397.
232.
Carreño V, Castillo I, Bartolomé J. Ultimos avances en hepatología.
Hepatol
Clin. 1998; 6: 59-88.
233.
López-Alcorocho JM, Amaro MJ, Cabrerizo M, Fogeda M, Castillo I,
Bartolomé J, Carreño V.
Phylogenetic analysis of hepatitis GB virus type C/hepatitis G virus in
Spanish patients with chronic hepatitis B or C virus infection. Intervirology
1998; 41: 233-237.
234.
López-Alcorocho JM, Castillo I, Tomás JF, Carreño
V. Identification of a novel GB type C virus/hepatitis G virus subtype in
patients with hematologic malignancies. J Med Virol 1999; 57: 80-84.
235.
Ruiz-Moreno M, Otero M, Millán A, Castillo I, Cabrerizo M, Jiménez FJ,
Oliva H, Ramón y Cajal S, Carreño V.
Clinical and histological outcome after hepatitis B e antigen to antibody
seroconversion in children with chronic hepatitis B. Hepatology 1999; 29:
572-575.
236.
Amaro MJ, Bartolomé J, Carreño
V. Hepatitis B virus X protein transactivates the inducible nitric oxide
synthase promoter. Hepatology 1999; 29: 915-923.
237.
Martín J, Navas S, Fernández M, Rico M, Pardo M, Quiroga JA, Zahm F, Carreño
V. In vitro effect of amantadine and interferon alpha 2a on hepatitis C
virus markers in cultured peripheral blood mononuclear cells from hepatitis C
virus infected patients. Antiviral Res 1999; 42: 59-70.
238.
Zeuzem S, Hopf U, Carreño V,
Diago M, Shiffman M, Grüne S, Dudley FJ, Rakhit
A, Rittweger K, Yap SH, Koff RS, Thomas HC. A phase
I/II study of recombinant
human interleukin-12 in patients with chronic hepatitis C. Hepatology 1999;
29: 1280-1287.
239.
Fogeda M, Navas S, Martín J, Casqueiro M, Rodríguez E, Arocena C, Carreño
V. In vitro infection of human peripheral blood mononuclear cells by GB
virus C/hepatitis G virus. J
Virol 1999; 73: 4052-4061.
240.
Manzano ML, Arocena C, Quiroga JA, Carreño
V. Alteraciones de la coagulación en las hepatopatías crónicas. Rev
Iber Tromb Hem 1999; 12: 38-40.
241.
Martín J, Quiroga JA, Navas S, Pardo M, Carreño
V. Modulation by biologic response modifiers of hepatitis C virus antigen-independent
cytokine secretion in blood mononuclear cells. Cytokine
1999; 11: 267-273.
242.
Carreño V. Ultimos avances en hepatología. Hepatol
Clin. 1999; 7: 25-42.
243.
Cabrerizo M, Bartolomé J, Otero M, Ruíz-Moreno M, Carreño
V. Sequence variation of hepatitis B virus
precore-core open reading frame
isolated from serum and liver of children with chronic hepatitis B before and
after interferon treatment. J Med Virol 1999; 58: 208-214.
244.
Rodríguez-Iñigo E, Bartolomé J, de Lucas S, Manzarbeitia F, Pardo M,
Arocena C, Gosálvez J, Oliva H, Carreño
V. Histological damage in chronic hepatitis C is not related to the extent
of infection in the liver. Am J Pathol 1999; 154: 1877-1881.
245.
Carreño V, Marcellin P, Hadziyannis S, Salmerón J, Diago M, Kitis
GE, Vafiadis I, Schalm SW, Zahm F, Manzarbeitia F, Jiménez FJ, Quiroga JA,
EUROHEP. Retreatment of chronic hepatitis B e
antigen-positive patients with
recombinant interferon-alpha 2a. Hepatology 1999; 30: 277-282.
246.
Janssen HLA, Gerken G, Carreño
V, Marcellin P, Naoumov NV, Craxi A, Ring-Larsen H, Kitis G, van Hattum J,
de Vries RA, Michielsen PP, ten Kate FJV, Hop WCJ, Heijtink RA, Honkoop P,
Schalm SW, EUROHEP. Interferon alfa for chronic hepatitis B
infection:
Increased efficacy of prolonged treatment. Hepatology 1999; 30: 238-243.
247.
Fernández M, Quiroga JA, Martín J, Herrero M, Pardo M, Horisberger MA,
Carreño V. In vivo and in vitro
induction of MxA protein in peripheral blood mononuclear cells from patients
chronically infected with hepatitis C virus. J Infect Dis 1999; 180: 262-267.
248.
Arocena C, Castillo I, Quiroga JA, Carreño
V. Ultimos avances en hepatología. Hepatol
Clin. 1999; 7: 73-100.
249.
Cabrerizo M, Bartolomé J, de Sequera P, Caramelo C, Manzano ML, Carreño
V. GBV-C/HGV-RNA in serum and peripheral blood mononuclear cells in
hemodialysis patients. Kidney
Int. 1999; 56: 1120-1128.
250.
Tomás JF, Rodríguez-Iñigo E, Bartolomé J, Alegre A, Fernández-Rañada
JM, Carreño V. Transplantation of
allogeneic CD34-selected peripheral stem cells does not prevent transmission
of hepatitis C virus from an infected donor. Bone Marrow Transplant 1999; 24:
109-112.
251.
Carreño V, Castillo I. Ultimos avances en hepatología. Hepatol
Clin. 1999; 7: 125-150.
252.
Carreño
V.
Ultimos avances en hepatología. Hepatol Clin. 1999; 7: 171-206.
253.
Albalate M, Martín J, de Sequera P, Quiroga JA, Olagüe C, Caramelo C,
Carreño V. Cinética del interferón a-2a
en pacientes en hemodiálisis. Nefrología 1999; 19: 268-270.
254.
Barril G, Bartolomé J, Traver JA, Cabrerizo M, Selgas R, Carreño
V. Autoclaving eliminates hepatitis C virus from a hemodialysis monitor
contaminated artificially. J
Med Virol 2000; 60: 139-143.
255.
Cotonat T, Quiroga JA, López-Alcorocho JM, Clouet R, Pardo M,
Manzarbeitia F, Carreño V. Pilot
study of combination therapy with ribavirin and interferon alfa por the
retreatment of chronic hepatitis B e antibody-positive patients. Hepatology
2000; 31: 502-506
256.
Carreño V, Martín J, Pardo M, Brotons A Anchía P,Navas S, Fernández
M, Arocena C, Quiroga JA. Randomized
controlled trial of recombinant human granulocyte-macrophage
colony-stimulating
factor for the treatment of chronic hepatitis C. Cytokine 2000; 12: 165-170.
257.
Carreño V, Zeuzem S, Hopf U, Marcellin P, Cooksley WGE, Fevery J,
Diago M, Reddy R, Peters M, Rittweger K, Rakhit A, Pardo M. A phase
I/II study
of recombinant human interleukin-12 in patients with chronic hepatitis B. J
Hepatol 2000; 32: 317-324.
258.
Rodríguez-Iñigo E, Casqueiro M, Bartolomé J, Barat A, Caramelo C,
Ortiz A, Albalate M, Oliva H, Manzano ML, Carreño
V. Hepatitis C virus RNA in kidney biopsies from infected patients with
renal diseases. J Viral Hepat 2000; 7: 23-29.
259.
Rodríguez-Iñigo E, Casqueiro M, Navas S, Bartolomé J, Pardo M, Carreño
V. Fluorescent "in situ" hybridization of hepatitis C virus RNA
in peripheral blood mononuclear cells from patients with chronic hepatitis C.
J Med Virol 2000; 60: 269-274.
260.
Barril G, López-Alcorocho JM, Bajo A, Ortiz-Movilla N, Sánchez-Tomero
JA, Bartolomé J, Selgas R, Carreño V. Prevalence of TT virus in serum
and peripheral mononuclear cells from a capd population. Periton Dialysis Int
2000; 20: 65-68.
261.
Manzano ML, Arocena C, Tomás JF, Hedner U, Quiroga JA, Carreño
V. Measurement of the procoagulant activity of factor VII in patients with
liver cirrhosis and normal prothrombin activity: evaluation of the bleeding
risk. Blood Coag Fibrinol 2000; 11 (Suppl 1): S95-S99.
262.
Rodríguez-Iñigo E, Casqueiro M, Bartolomé J, Ortiz-Movilla N, López-Alcorocho
JM, Herrero M, Manzarbeitia F, Oliva H, Carreño
V. Detection of TT virus DNA in liver biopsies by in situ
hybridization.
Am J Pathol 2000; 156: 1227-1234.
263.
Arrieta JJ, Rodríguez-Iñigo
E, Casqueiro M, Bartolomé J, Manzarbeitia F, Herrero M, Pardo M, Carreño
V. Detection of hepatitis C virus replication by in situ hybridization in
epithelial cells of anti-hepatitis C virus-positive patients with and without
oral lichen planus. Hepatology 2000; 32: 97-103.
264.
Madejón
A, Manzano ML, Arocena C, Castillo I, Carreño
V. Effects of delayed freezing of liver biopsies on the detection of
hepatitis C virus RNA strands. J
Hepatol 2000; 32: 1019-1025.
265.
Carreño
V
y los miembros de la Fundación para el Estudio de las Hepatitis Virales.
Ultimos avances en hepatología. Hepatol Clin. 2000; 8: 3-57.
266.
Cabrerizo M, Bartolomé J, Caramelo C, Barril G, Carreño
V. Molecular analysis of hepatitis B virus DNA in serum and peripheral
blood mononuclear cells from hepatitis B surface antigen-negative cases.
Hepatology 2000; 32: 116-123.
267.
Martín J, de Sequera P, Quiroga JA, Rico M, Fernández M, Arocena C,
Caramelo C, Carreño V. Role of
haemodialysis and hepatitis C virus infection in spontaneous and induced
cytokine production of patients with chronic renal disease. Cytokine 2000; 12:
1248-1252.
268.
Fogeda M, López-Alcorocho JM, Bartolomé J, Arocena C, Martín MA, Carreño
V. Existence of distinct GB virus C/hepatitis G virus variants with
different tropism. J Virol 2000; 74: 7936-7942.
269.
López-Alcorocho JM, Mariscal LF, de Lucas S, Rodríguez-Iñigo E,
Casqueiro M, Castillo I, Bartolomé J, Herrero M, Manzano ML, Pardo M, Carreño
V. Presence of TTV DNA in serum, liver and peripheral blood mononuclear
cells from patients with chronic hepatitis. J Viral Hepat 2000; 7: 440-447.
270.
Carreño
V
y los miembros de la Fundación para el Estudio de las Hepatitis Virales.
Ultimos avances en hepatología. Hepatol
Clin. 2000; 8: 59-104.
271.
Carreño
V.
y los miembros de la Fundación para el Estudio de las Hepatitis Virales.
Ultimos avances en hepatología. Hepatol Clin. 2000; 8: 105-146.
272.
Carreño
V.
y los miembros de la Fundación para el Estudio de las Hepatitis Virales.
Ultimos avances en hepatología. Hepatol
Clin. 2000; 8:147-190.
273.
Rico MA, Quiroga JA, Subirá D, Castañón S, Esteban JM, Pardo M, Carreño
V. Hepatitis B virus-specific T-cell proliferation and cytokine secretion
in chronic hepatitis B e antibody-positive patients treated with ribavirin and
interferon-alfa. Hepatology 2001; 33: 295-300.
274.
de Lucas S, Bartolomé J, Rodríguez-Iñigo E, Casqueiro M, Millán A,
Ruiz-Moreno M, Oliva H, Carreño V. Distribution of hepatitis C virus
infection in liver biopsies from children and adults with chronic hepatitis C.
J Med Virol 2001; 64: 1-5.
275.
López-Alcorocho JM, Barril G, Ortiz-Movilla N, Traver JA, Bartolomé
J, Sanz P, Selgas R, Carreño V. Prevalence of hepatitis B, hepatitis
C, GB virus C/hepatitis G and TT viruses in predialysis and hemodialysis
patients. J Med Virol 2001; 63: 103-107.
276.
Arrieta
JJ, Rodríguez-Iñigo E, Ortiz-Movilla N, Bartolomé J, Pardo M, Manzarbeitia
F, Oliva H, Carreño V. In situ detection of hepatitis C virus RNA in salivary
glands. Am
J Pathol 2001; 158: 259-264.
277.
Rodríguez-Iñigo E, Bartolomé J, Quiroga JA, Hedner U, Suárez A, Tomás
JF, Manzarbeitia F, Arocena C, Manzano ML, Oliva H, Carreño V.
Expression of factor VII in the liver of patients with liver disease:
correlations with the disease severity and impairment in the hemostasis. Blood
Coag Fibrinol 2001; 12: 1-7.
278.
Rodríguez-Iñigo
E, Arrieta JJ, Casqueiro M, Bartolomé J, López-Alcorocho JM, Ortiz-Movilla
N, Manzarbeitia F, Pardo M, Carreño V. TT virus detection in oral
lichen planus lesions. J
Med Virol 2001; 64: 183-189.
279.
Diago M, Suárez D, García-Villarreal L, Castro A, Domínguez A, Pardo
M, del Olmo JA, Pérez-Hernández F, Aguilar J, Quiroga JA, Carreño V.
Multicenter randomized study comparing initial daily induction with high dose
lymphoblastoid interferon vs. standard interferon treatment for chronic
hepatitis C. J Med Virol 2001; 64: 460-465.
280.
Carreño
V,
Rico MA, Pardo M, Quiroga JA. Extended
follow-up of anti-HBe-positive patients with chronic hepatitis B retreated
with ribavirin and interferon-alpha. Antiviral Res 2001; 52: 147-152.
281.
García-Jiménez ME, Quiroga JA, Gutiérrez ML, Pardo M, Carreño V.
Association of HLA-DR genes with mild idiopathic adulthood biliary ductopenia.
Am J Gastroenterol 2001; 96: 1178-1182.
282.
Zeuzem S, Carreño V. Interleukin-12 in the treatment of chronic
hepatitis B and C. Antiviral Res 2001; 52: 181-188.
283.
Rico
MA, Quiroga JA, Subirá D, García E, Castañón S, Sällberg M, Leroux-Roels
G, Weiland O, Pardo M, Carreño V. Features of
the CD+ T-cell response in liver and peripheral blood of hepatitis C
virus-infected
patients with persistently normal and abnormal alanine aminotransferase levels.
J
Hepatol 2002; 36: 408.
284. Pardo M, Bartolomé J, Carreño V. Recombinant activated factor VII prevents bleeding during a surgical procedure in a patient with uncontrollable rectal hemorrhage. Am J Gastroenterol 2002; 97: 1266-1267.
285.
286.
287.
288.
289.
290.
291.
292. Fernández M, Quiroga JA, Carreño V. Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins. J Gen Virol 2003; 84: 2073-2082.
293.
294.
295.
296.
297.
298. Hultgren C, Desombere I, Leroux-Roels G, Quiroga JA, Carreno V, Nilsson B, Weiland O, Sällberg M. Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses. J Hepatol 2004;40:971-8.
299. Mariscal LF, Rodríguez-Iñigo E, Bartolomé J, Castillo I, Ortiz-Movilla N, Navacerrada C, Pardo M, Pérez-Mota A, Graus J, Carreño V. Hepatitis B infection of the liver in chronic hepatitis C without detectable hepatitis B virus DNA in serum. J Med Virol 2004;73:177-86.
300. Barril G, González Parra E, Alcázar R, Arenas D, Campistol JM, Caramelo C, Carrasco M, Carreño V, Espinosa M, García Valdecasas J, Górriz JL, López MD, Martín L, Ruiz P, Terruel JL; Spanish Society of Nephrology.[Guidelines on hemodialysis-associated viral infections] Nefrologia 2004;24 Suppl 2:43-66. Review.
301. Carreño V, Castillo I, Bartolomé J, Rodríguez-Iñigo E, Ortiz-Movilla N, de Lucas S, Pardo M. Comparison of hepatitis C virus RNA detection in plasma, whole blood and peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. J Clin Virol 2004;31:312-3.
302. Lucas Sd S, López-Alcorocho JM, Bartolomé J, Carreño V. Nitric oxide and TGF-beta1 inhibit HNF-4alpha function in HEPG2 cells. Biochem Biophys Res Commun 2004;321:688-94.
303. Barril G, Quiroga JA, Sanz P, Rodrìguez-Salvanés F, Selgas R, Carreño V. Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers. Aliment Pharmacol Ther 2004;20:37-44.
304. Quiroga JA, Carreño V. HCV-indeterminate blood donors or occult HCV infection? Lancet 2005;365:1540-1.
305. Castillo I, Rodríguez-Iñigo E, Bartolomé J, de Lucas S, Ortíz-Movilla N, López-Alcorocho JM, Pardo M, Carreño V. Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut 2005;54:682-5.
306. de Lucas S, Bartolome J, Carreno V. Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. J Infect Dis 2005;19:93-9.
307. Rodríguez-Iñigo E, Bartolomé J, Ortiz-Movilla N, Platero C, López-Alcorocho JM, Pardo M, Castillo I, Carreño V. Hepatitis C virus (HCV) and hepatitis B virus (HBV) can coinfect the same hepatocyte in the liver of patients with chronic HCV and occult HBV infection. J Virol 2005;79:15578-81.
308. Rodríguez-Iñigo E, López-Alcorocho JM, Bartolomé J, Ortiz-Movilla N, Pardo M, Carreño V. Percentage of hepatitis C virus-infected hepatocytes is a better predictor of response than serum viremia levels. J Mol Diagn 2005;7:535-43.
309. Rodríguez-Iñigo E, Jiménez E, Bartolomé J, Ortiz-Movilla N, Bartolomé Villar B, José Arrieta J, Manzarbeitia F, Carreño V. Detection of human immunodeficiency virus type 1 RNA by in situ hybridization in oral mucosa epithelial cells from anti-HIV-1 positive patients. J Med Virol 2005;77:17-22.
310. Carreño V, Pardo M, López-Alcorocho JM, Rodríguez-Iñigo E, Bartolomé J, Castillo I. Detection of hepatitis C virus (HCV) RNA in the liver of healthy, anti-HCV antibody-positive, serum HCV RNA-negative patients with normal alanine aminotransferase levels. J Infect Dis 2006;194:53-60.
311. Pardo M, López-Alcorocho JM, Castillo I, Rodríguez-Iñigo E, Perez-Mota A, Carreño V. Effect of anti-viral therapy for occult hepatitis C virus infection. Aliment Pharmacol Ther 2006;23:1153-9.
312. Rodríguez-Casado A, Bartolomé J, Carreño V, Molina M, Carmona P. Structural characterization of the 5' untranslated RNA of hepatitis C virus by vibrational spectroscopy. Biophys Chem 2006;124:73-9..
313. Quiroga JA, Llorente S, Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Pardo M, Carreño V. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection. J Med Virol 2006;78:1190-7.
314. Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Pardo M, Bartolomé J, Carreño V Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 2006;43:1277-83.
315. Quiroga JA, Castillo I, Pardo M, Rodríguez-Iñigo E, Carreño V. Combined hepatitis C virus (HCV) antigen-antibody detection assay does not improve diagnosis for seronegative individuals with occult HCV infection. J Clin Microbiol 2006;44:4559-60.
316. Quiroga JA, Llorente S, Castillo I, Rodríguez-Iñigo E, Pardo M, Carreño V. Cellular immune responses associated with occult hepatitis C virus infection of the liver. J Virol 2006;80:10972-9.
317. Carreño V. Occult hepatitis C virus infection: a new form of hepatitis C. World J Gastroenterol 2006;12:6922-5.
318. López-Alcorocho JM, Rodríguez-Iñigo E, Castillo I, Castellanos ME, Pardo M, Bartolomé J, Quiroga JA, Carreño V. The role of genomic and antigenomic HCV-RNA strands as predictive factors of response to pegylated interferon plus ribavirin therapy. Aliment Pharmacol Ther 2007;25:1193-201.
319. Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Bartolomé J, Pardo M, Carreño V. Comparative study on the clinical and virological characteristics among patients with single occult hepatitis B virus (HBV), single occult hepatitis C virus (HCV) and occult HBV and HCV dual infection. J Med Virol 2007;79:236-41.
320. Pardo M, López-Alcorocho JM, Rodríguez-Iñigo E, Castillo I, Carreño V. Comparative study between occult hepatitis C virus infection and chronic hepatitis C. J Viral Hepat 2007;14:36-40.
321. Bartolomé J, López-Alcorocho JM, Castillo I, Rodríguez-Iñigo E, Quiroga JA, Palacios R, Carreño V. Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. J Virol 2007;81:7710-5.
322. Desombere I, Van Vlierberghe H, Weiland O, Hultgren C, Sällberg M, Quiroga J, Carreño V, Leroux-Roels G. Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C. J Med Virol 2007;79:701-13.
323. Pardo M, Bartolomé J, Carreño V. Current therapy of chronic hepatitis B. Arch Med Res 2007;38:661-77. Review.
324. Quiroga JA, Castillo I, Bartolomé J, Carreño V. Serum immunoglobulin G antibodies to the GOR autoepitope are present in patients with occult hepatitis C virus (HCV) infection despite lack of HCV-specific antibodies. Clin Vaccine Immunol 2007;14:1302-6.Virol 2006 (in press).
325. Bartolomé J, Rodríguez-Iñigo E, Erice A, Vidal S, Castillo I, Carreño V. Hepatitis C virus does not infect muscle, the intervertebral disk, or the meniscus in patients with chronic hepatitis C. J Med Virol 2007;79:1818-20.
326. Carreño V, Bartolomé J, Castillo I, Quiroga JA. Occult hepatitis B virus and hepatitis C virus infections. Rev Med Virol 2008;18:139-57. Review.
327. Bartolomé J, Rodríguez-Iñigo E, Quadros P, Vidal S, Pascual-Miguelañez I, Rodríguez-Montes JA, García-Sancho L, Carreño V. Detection of hepatitis C virus in thyroid tissue from patients with chronic HCV infection. J Med Virol 2008;80:1588-94.
328. Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernández N, González-Parra E, Alcazar JM, Sánchez C, Diez-Baylón JC, Martinez P, Bartolomé J, Carreño V. Occult Hepatitis C Virus Infection among Hemodialysis Patients. J Am Soc Nephrol 2008 Dec;19(12):2288-92. Epub 2008 Aug 6.
329. Does occult hepatitis C virus infection exist? Carreño V, Bartolomé J, Castillo I, Quiroga JA.J Clin Microbiol. 2008 Oct;46(10):3550; author reply 3550-2. No abstract available.
330. Identification of serologically silent occult hepatitis C virus infection by detecting immunoglobulin G antibody to a dominant HCV core peptide epitope. Quiroga JA, Castillo I, Llorente S, Bartolomé J, Barril G, Carreño V.J Hepatol. 2009 Feb;50(2):256-63. Epub 2008 Nov 4.